Enzon Pharmaceuticals (NASDAQ:ENZN) recently announced its plans to halt studies of its PEG-SN38 program for the treatment of metastatic colorectal cancer (mCRC). PEG-SN38 (EZN-2208) is a PEGylated version of the active metabolite of the cancer drug, irinotecan. The study is being discontinued in order to focus resources to other areas with nearer-term commercial potential. A mid-stage study of the program in this indication had recently concluded. Enzon however continues studies of the PEG-SN38 ? [visit site to read more] or compare Best Credit Cards and Balance Transfer Credit Cards
Source: http://getcreditscore101.com/whatisagoodcreditscore/10443/enzon-stops-colorectal-cancer-study/
gabriel ping pong ratatouille elmo bradley manning movie times enchanted
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.